摘要
目的:研究小剂量米非司酮片联合橘荔散结片对子宫肌瘤患者雌、孕激素的影响。方法 :选取2016年5月—2017年8月我院收治的93例子宫肌瘤患者,按照治疗方案的不同分为研究组(47例)和对照组(46例)。对照组采用橘荔散结片(6.0 g,tid)治疗,研究组采用橘荔散结片联合米非司酮片(5 mg,于月经周期的第一天开始,每周服用2次)治疗,比较两组血清中孕酮(P)、雌二醇(E_2)、黄体生成素(LH)和卵泡刺激素(FSH)水平,子宫肌瘤体积、肌瘤缩小率以及临床疗效。结果 :治疗后,两组血清E_2、P、FSH、LH水平及子宫肌瘤体积均低于治疗前,且研究组低于对照组,差异有统计学意义(P <0.05)。研究组治疗总有效率及肌瘤缩小率高于对照组,差异有统计学意义(P <0.05)。结论 :小剂量米非司酮片联合橘荔散结片治疗子宫肌瘤疗效显著,可降低患者雌、孕激素,明显缩小子宫肌瘤体积,且安全性高。
Objective:To investigate the effect of low-dose mifepristone tablets combined with juli sanjie tablets on estrogen and progesterone in patients with hysteromyoma.Methods:93 patients with hysteromyoma admitted to our hospital from May 2016 to August 2017 were selected and divided into a study group(47 cases)and a control group(46 cases)according to different treatment options.The patients in the control group were treated with juli sanjie tablets(6.0 g,tid),and the patients in the study group were treated with juli sanjie tablets combined with mifepristone tablets(5 mg,twice a week from the first day of the menstrual cycle).The levels of serum progesterone(P),estradiol(E2),luteinizing hormone(LH)and follicle stimulating hormone(FSH),hysteromyoma volume,hysteromyoma reduction rate and clinical efficacy were compared between the two groups.Results:The levels of serum E2,P,FSH and LH and the volume of hysteromyoma in the two groups after treatment were lower than those before treatment,and the levels and the volume in the study group were lower than those in the control group,with statistically significant differences(P<0.05).The total effective rate of the treatment and the rate of hysteromyoma reduction in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:Low-dose mifepristone tablets combined with juli sanjie tablets are significantly effective in the treatment of hysteromyoma,which can reduce estrogen and progesterone in the patients and significantly reduce the volume of hysteromyoma,and have high safety.
作者
张雪莹
曹海英
赵盼
Zhang Xue-ying;Cao Hai-ying;Zhao Pan(Department of Obstetrics and Gynecology,Zhumadian Central Hospital,Zhumadian Henan 463000,China)
出处
《中国合理用药探索》
CAS
2019年第4期54-57,共4页
Chinese Journal of Rational Drug Use